2012 Annual Report

COPD
Foundation
2012
ANNUAL REPORT
July 1, 2011 - June 30 , 2012
The mission of the COPD
Foundation is to develop and
support programs which improve
the quality of life through
research, education, early
diagnosis, and enhanced therapy
for persons whose lives are
impacted by Chronic Obstructive
Pulmonary Disease (COPD).
COPD FOUNDATION 2012 Annual Report
1
Message from
the leadership
Greetings,
This past Fiscal Year (July 1, 2011 – June 30, 2012) was a remarkable one for the COPD Foundation, and we would like
to express our deepest appreciation to all of you for your continued support. The progress we have made in the past
year was only possible because of your dedication and generosity. When the COPD Foundation was established, our
primary goal was to increase COPD research and accelerate the development of more effective therapies for COPD.
We found that to ultimately accomplish these goals, we needed to increase awareness, advocacy and education
for individuals with COPD, their families and their healthcare providers. We are pleased to report that we’re making
progress in each of these areas.
In the fall of 2011, Boehringer Ingelheim Pharmaceuticals, Inc. requested proposals from not-for-profit organizations
interested in taking over the leadership of DRIVE4COPD, the nation’s single largest public awareness campaign
for COPD. With the hard work of our dedicated staff, the COPD Foundation was ultimately successful in being
awarded the campaign and for assuming responsibility for the continuation of the identification and screening of
the 12 million Americans not yet diagnosed with COPD in April 2012. Designated as the Official Health Initiative of
NASCAR, the DRIVE4COPD campaign sponsored the DRIVE4COPD300 NASCAR race held at the Daytona International
Speedway in Florida in February 2012. This event was the most viewed NASCAR Nationwide Series event in cable
history, with an average of 3.3 million households and 4.4 million viewers tuning in to the race. As a result of this
event, the DRIVE4COPD campaign raised awareness among NASCAR fans, teams, drivers and sponsors and raised the
profile on this important cause. The DRIVE4COPD campaign continued its momentum into March 2012 by hosting
the DRIVE4COPD Celebrity Pro-Am Racing Challenge held at Auto Club Speedway in Fontana, California. During
this event, high profile celebrities and athletes drove media exposure while supporting this important fundraising
initiative. In addition to more than $150,000 raised in funds, ten public service announcements were filmed which will
be used to support the campaign and raise awareness for the disease.
Also this year, the COPD Biomarkers Qualification Consortium (CBQC) submitted an Initial Briefing Package to the Food
and Drug Administration (FDA), formally starting the qualification process for 3 biomarkers as measures of quality
of life: The St. George’s Respiratory Questionnaire for COPD Patients Manual (SGRQ), the six-minute walk test and
Plasma Fibrinogen. These “biomarkers” identify COPD patients at risk. We have received positive responses from the
FDA about these proposals and are hopeful they will all move forward to qualification. These biomarkers and others
we will submit in the coming years should dramatically increase the number of approved endpoints for clinical trials,
ultimately accelerating the development of more effective treatments. It is clear that the role of the COPD Foundation
has been critical in this process. Over the next year we plan to push the growth of our COPD Research Registries—
enrolling thousands of people with COPD who have agreed to make themselves available—to participate in clinical
research supporting our commitment to new drug development for better treatments and some day a cure. Similarly,
our Bronchiectasis Research Registry has grown to 15 medical centers with a registry of over 1,500 people with noncystic fibrosis related bronchiectasis; by far the largest registry ever developed in this population.
Our Case-Finding Study was published this year, with the goal of identifying undiagnosed patients and better defining
who requires a spirometry test to make a COPD diagnosis. The National Heart, Lung and Blood Institute (NHLBI)
which partnered with the COPD Foundation in holding a Case Finding workshop four years ago, awarded a grant to
2
COPD FOUNDATION 2012 Annual Report
a consortium of several of the largest academic medical centers in the country, including the COPD Foundation, to
develop a more comprehensive case finding protocol to advance early diagnosis.
We have continued pushing forward with our education efforts. Our ever-popular Slim Skinny Reference Guides and
our Big Fat Reference Guide have been updated and remain a vital resource for individuals with COPD. Most of our
educational materials have been translated into German, Spanish and Chinese. We plan to broaden our translations to
other languages in the coming year.
Every other year for 15 years, investigators in Europe have been holding a major COPD conference in Birmingham,
England. This conference has become the major COPD educational conference in the world. The COPD Foundation has
partnered with the leadership of this European conference to bring this series to the United States. Last December in
Washington, DC we hosted the COPD7USA Conference in conjunction with the Second National U.S. COPD Coalition
Conference. In June 2013, we plan on hosting COPD8USA in Chicago.
Our advocacy program has continued to grow with more states organizing COPD Coalitions and more individuals
signing up as COPD advocates through our Operation 435 Advocacy Program. Our C.O.P.D. Information Line has
responded to an exponential increase in call volume and now provides outbound call services, which will dramatically
improve our ability to help those we are striving to serve.
As we enter into the new year, we can build upon our progress of this past year with the commitment to intensify our
efforts to increase awareness and organize a coordinated federal and state action plan to support research, education,
access to care and to accelerate the development of new therapies. We need to make certain that everyone with COPD
is properly diagnosed, is appropriately treated and has access to the information and resources they need to improve
the quality of their lives. As we say here at the COPD Foundation, “COPD is almost always preventable, almost always
treatable, and someday curable”.
The COPD Foundation’s research, education and support programs are made possible by the generosity of our many
donors. We shall be forever grateful for your incredible support and encourage all those living with COPD to join with
us, take action, and make a difference.
John W. Walsh
Byron M. Thomashow, MD
President and Co-Founder,
COPD Foundation
Chair, Board of Directors, and
Co-Founder, COPD Foundation
COPD FOUNDATION 2012 Annual Report
3
Board of
directors
Executive Committee
Byron M. Thomashow, MD
Chair
New York, NY
Wayne E. (Chip) Withers, Jr.
Vice Chair
Coral Gables, FL
Stephen I. Rennard, MD
Scientific Advisor
Omaha, NE
Gerard M. Turino, MD
Immediate Past Chair
New York, NY
Donald Gray
Treasurer/Secretary
Bronxville, NY
John W. Walsh
President
Miami, FL
Members
Pamela R. Bird, PhD
Sandpoint, ID
Chip Gatchell
Nashua, NH
Ab Rees
Kansas City, MO
Gordon E. Cadwgan Jr., PhD
West Palm Beach, FL
Sam P. Giordano, MBA, RRT, FAARC
Irving, TX
Lawrence D. Stern
Pittsburgh, PA
Stew Cogan, Esq.
Seattle, WA
David M. Mannino, MD
Lexington, KY
James K. Stoller, MD., M.S.
Cleveland, OH
James D. Crapo, MD
Denver, CO
Michael P. Mayer
Berwyn, PA
Alvin V. Thomas Jr., MD, FACP, FCCP
Washington, DC
4
COPD FOUNDATION 2012 Annual Report
Activities &
accomplishments
Education/Awareness
Communications
COPD Shuttle: Journey to the
Center of the Lung
Annual Report
COPD Digest Magazine
DRIVE4COPD® Campaign
Digital & Social Media Outreach
Mobile Spirometry Unit
Faces of COPD Blog
Call Our Patients Direct (C.O.P.D.)
Information Line
Journal of COPD
1’s 2’s and 3’s of COPD
COPD Big Fat Reference Guide (BFRG)®
Slim Skinny Reference Guides (SSRG) ®
Lung Health Professional Magazine
Research
COPD Biomarkers Qualification Consortium
COPDGene® Study
COPD Research Registry
Pocket Consultant Card
Bronchieactasis Research Consortium
and Registry
Pulmonary Education Program (PEP)
Public Policy
COPD Education Conversation Map Project
Lung Health Check
Medical Professional Education Events
Medscape CME Collaboration
Operation 435
Behavioral Risk Factor Surveillance System
Advocacy Events
U.S. COPD Coalition
COPD FOUNDATION 2012 Annual Report
5
highlights
DRIVE4COPD®
The DRIVE4COPD campaign is a landmark public
health initiative that aims to raise awareness of
COPD, drive earlier diagnosis through risk screening,
champion access to needed care and services, and
advance efforts to help people with COPD live full and
productive lives.
To date, the campaign has screened more than 2.5
million people to see if they are at risk for COPD. By expanding its educational outreach, driving earlier diagnosis
through risk screening, serving as a resource for those diagnosed and advocating for improvements in care, the COPD
Foundation will further transition DRIVE4COPD into a comprehensive campaign, moving well beyond screening and
awareness. The DRIVE4COPD campaign will focus on seven initiatives. Highlights of these initiatives include a COPD
employer toolkit aimed at businesses including Fortune 500 companies partnering with NASCAR and the Advocacy
Driver’s License Program in which members of the COPD community are organized and trained to become advocates
for increased federal funding for COPD research and education.
Biomarkers Qualification Consortium
The COPD Foundation’s COPD Biomarker Qualification Consortium (CBQC) submitted an Initial Briefing Package to the
Food and Drug Administration (FDA), formally starting the qualification process for Plasma Fibrinogen as a “biomarker”
identifying COPD patients at risk for hospitalization and death.
Fibrinogen, a protein that can be measured in the blood, is a very promising biomarker. There is strong evidence of
an association of fibrinogen with COPD, the presence and frequency of exacerbations and with death. It is likely to
be a useful biomarker to categorize individuals with COPD who might have more chance of a poor health and also
determine which patients have a better chance of responding to
specific treatments.
The COPD Foundation organized the CBQC as a public-private
partnership, a true example of collaboration between a group of
academic researchers, pharmaceutical companies and government
agencies that are working toward the common goal of finding better
and faster ways to develop new treatments for COPD.
The introduction of new biomarkers is beneficial to the COPD
community because it may lead to accelerating the development
of more targeted therapies and optimizing the efforts of the FDA
and pharmaceutical companies in the approval of new therapies to
improve the quality of life for individuals with COPD.
6
COPD FOUNDATION 2012 Annual Report
Bronchieactasis Research Registry
The Bronchiectasis Research Registry was established in 2008 and is a consolidated database of non-Cystic Fibrosis
(non-CF) Bronchiectasis patients, enrolled by a consortium of 15 clinical institutions nationwide. The goal of the
Registry is to support collaborative research and assist in recruiting patients for research studies to improve treatment
for non-CF Bronchiectasis patients. As of the end of June 2012, the Bronchiectasis Research Registry Consortium has
enrolled nearly 1,300 patients. The COPD Foundation is currently investigating expanding the Registry Consortium
internationally. The COPD Foundation is also in the process of formulating a Bronchiectasis Research Registry Industry
Advisory Committee in which industry partners will have the opportunity to collaboratively work with the Registry’s
Consortium members to conduct clinical trials in conjunction with the Registry’s patients.
The Bronchiectasis Research Registry has also collaborated with another not for profit, NTM Info & Research, to expand
data collection by the Registry’s Consortium members to include NTM (Nontuberculous Mycobacteria). NTM is an
often misdiagnosed orphan disease that can cause severe lung infections that mimic tuberculosis and individuals
can become infected with NTM through environmental exposure to water, including potable water supplies, and soil
through inhalation, ingestion and breaks in the skin due to injuries, surgical procedures, or IV catheters. Many patients
with NTM also have Bronchiectasis, and vice versa, and have underlying lung problems such as Bronchiectasis or other
forms of COPD, Cystic Fibrosis or Alpha-1 Antitrypsin Deficiency.
COPDGene® Study
The COPDGene® study cohort consists of 10,364 individuals who have COPD or are risk of developing COPD. The
objective of the study is to analyze genetic variations to identify the primary genes that determine why some
individuals are more susceptible to developing COPD than others. Identifying
genetic factors that contribute to this disease will help us understand the biological
mechanisms involved, which will ultimately lead to better treatments and improved
outcomes for patients. It is well known that not all smokers develop COPD; therefore
the results of this study could change how researchers, healthcare professionals,
public officials and the general public view COPD. Patient enrollment for the study
concluded in March 2011, but patients are being followed longitudinally. The COPD
Foundation has solicited a nd received more than 4 million dollars for ancillary studies,
longitudinal follow-up and activities that were not included in the Study’s budget
from the National Heart, Lung and Blood Institute (NHLBI) with additional support
from the COPD Foundation’s COPDGene® Study’s Industry Advisory Committee
partners. During the first five years of the COPDGene® study, 47 papers were
published and 69 ancillary studies were approved.
The COPD Foundation is proud to announce that NHLBI funding has been awarded
for the second phase of the COPDGene® Study. In the second phase of this study,
follow-up visits, at a five-year interval from the initial visit, will be done on all available
COPDGene® participants in order to determine longitudinal changes in disease
development and progression. The specific aims of the second phase of the study
include the following: 1) Characterize the determinants of COPD progression over
five years using clinical phenotyping and both quantitative and visual analysis of chest CT scans; 2) Assess the rare
and common genetic determinants of COPD and COPD-related phenotypes by genotyping with the Exome Chip in
over 10,000 participants, followed by whole genome sequencing in a subset of the cohort; and 3) Develop a new
classification system based on pathophysiologic subtypes of COPD by integrating genetic, clinical, physiologic,
and CT-based phenotypes. Accomplishment of these aims is expected to lay a foundation for the development of
personalized therapy for specific subtypes of COPD.
COPD FOUNDATION 2012 Annual Report
7
C.O.P.D. Information Line
Individuals with COPD and their caregivers are often in need of education, support, and resources for their disease
management. In some cases, they need to speak with someone one-on-one who can provide assistance, empathy
and support. In 2007, the COPD Foundation addressed this need by establishing the Call Our Patients Direct (C.O.P.D)
Information Line in conjunction with the National Heart, Lung, and Blood Institute (NHLBI) to educate and spread
advocacy for COPD awareness.
Today, the C.O.P.D. Information Line, 866-316-COPD (2673), is a toll-free
number for information & referrals on COPD by patients and caregivers
impacted by COPD. No medical advice is provided.
Initially, the Information Line solely addressed the needs of COPD patients,
but the need for caregiver support quickly became evident. The toll-free
number, 1-866-316-COPD (2673) now provides peer-to-peer connections
to those living with COPD and COPD caregivers with support in English,
Spanish, French and Italian as well as translation capabilities in over 175
languages.
All Associates are trained over a rigorous 45-hour process on customer
service and call etiquette, service to sales, Health Insurance Portability and
Accountability Act (HIPAA) compliance, disease management information,
COPD Foundation program information, and research initiatives. The
Associates are comprised of individuals with COPD, caregivers or medical
professionals from within the community.
From July 2011 through June 2012, the Information Line handled over
44,000 individual contacts that included telephone, email and chat. The
average contact volumes are steadily over 4,000 a month - more than 100 individuals reached daily.
There are significant plans to expand the outbound calling capacity of the Information Line with a focus on engaging
our constituents more in our programs.
The Information Line is an invaluable tool that identifies the pressing needs of the community, including all
stakeholders - patients, caregivers and their healthcare providers.
8
COPD FOUNDATION 2012 Annual Report
financial statements
The following pages include financial information for the COPD Foundation’s 2012 Fiscal Year. This year presented
additional growth of donations received, both in grants received and public donations. The COPD Foundation thanks
all of its supporters. Every dollar of the monies received went to supporting the COPD Foundation’s mission to help
improve the lives of individuals living with COPD—both diagnosed and undiagnosed.
Statement of Financial Position
Year Ended June 30,
2012
2011
Assets
Current Assets
Cash (includes $129,976 and $274,757, respectively,
which has been restricted by the donor)
Marketable securities
Accounts receivable
Due from Respiratory Logistics
Other assets
Total current assets
Marketable securities - non-current
Investments in Repiratory Logistics
Property and equipment, net
Total assets
$3,484,371$1,934,204
1,486,969
1,352,779
494,921
796,280
8,184
14,327
19,449
5,488,7724,102,712
254,500
250,000
21,498
209,956
250,000
20,937
$4,583,605 $2,468,986
Liabilities and Net Assets
Current Liabilities
Accounts payable and accrued expenses
Due to Alpha-1 Foundation
$390,700$405,685
5,285
22,719
Total current liabilities
395,985
428,404
Net Assets
Unrestricted
Temporarily restricted
Total net assets
Total liabilities and net assets
547,283282,581
5,071,502
3,872,620
5,618,7854,155,201
$6,014,770$4,583,605
COPD FOUNDATION 2012 Annual Report
9
Statement of Activities and Changes in Net Assets
Year Ended June 30,
2012
2011
Changes in Unrestricted Net Assets
Unrestricted Support and Revenue
Contributions, bequests and grant revenues
Investment income, net
Other income
Net assets released from restriction-satisfaction
of program restrictions
Total unrestricted support and revenue
$1,335,515 180,281
817,037
$1,190,7608
128,938
560,434
4,781,6281,989,730
$7,114,461 $3,869,862
Unrestricted Expenses
Program Services
DRIVE4COPD
COPD Gene Study
COPD Patient Education
COPD Biomarkers Qualification Consortium
COPD Publications
COPD Information Line
COPD Public Policy
COPD Research Network
COPD Mobile Spirometry Unit
Total program service
Supporting Services
Fund Raising Administration and general
Total supporting service
Total unrestricted expenses
(Decrease) Increase in unrestricted net assets
1,706,846 1,065,665
1,063,884 490,114 444,439
366,574 327,796
292,182
197,719
-
459,917
480,285
398,290
597,653
228,992
326,567
294,212
254,593
5,955,219
3,040,509
489,217
405,323
449,214
401,859
894,540
851,073
6,849,759
3,891,582
264,702
(21,720)
5,980,510
(4,781,628)
4,165,771
(1,989,730)
Changes in Temporarily Restricted Net Assets
Contributions, bequests and grant revenues
Net assets released from restriction
10
Increase in temporarily restricted net assets
1,198,882
2,176,041
Increase in net assets
Net assets, beginning of year
1,463,584
4,155,201
2,154,321
2,000,880
Net assets, end of year
$5,618,785
$4,155,201
COPD FOUNDATION 2012 Annual Report
0,000
0,000
COPD Foundation Functional Expenses
For The Fiscal Year Ended June 30, 2012
Mobile
Spirometry Unit
3%
COPD Research
4%
COPD Gene Study
16%
DRIVE4COPD
25%
Mobile
Spirometry Unit
3%
COPD Research
4%
COPD Gene Study
16%
DRIVE4COPD
25%
Information Line
5%
Information Line
5%
CBQC
7%
CBQC
7%
Public Policy
5%
Publications
6%
Fund Raising
7%
Public Policy
5%
Publications
6%
COPD Education
16%
Administration
6%
Fund Raising
7%
Investment Income
$128,938
2%
Other Support
$900,505
15%
Administration
6%
COPD Education
16%
Program Service Income
$548,684
9%
Corporate Contributions
4,467,776
74%
COPD Foundation Total Revenue
Fiscal Year 2004 - Fiscal Year 2012
Investment Income
$128,938
2%
Other Support
$900,505
15%
$9,000,000
$8,313,343*
$8,000,000
Program Service Income
$548,684
$7,000,000
9%
Corporate Contributions
4,467,776
74%
$6,045,903
$6,000,000
$5,000,000
$4,284,697
$3,772,231
$4,000,000
$3,000,000
$2,260,889
$2,000,000
$1,405,463
$1,000,000
$485,770
$52,395
0
2004
$117,745
2005
2006
2007
2008
2009
2010
2011
2012
*Total revenue refers to total unrestricted support and revenue, plus (minus) the increase (decrease) in temporarily restricted net assets.
COPD FOUNDATION 2012 Annual Report
11
$8,31
COPD F o u n d a t i o n
Heritage society
The COPD Foundation is pleased to announce the debut of the COPD Foundation Heritage Society – a program to
ensure the continued success of the COPD Foundation and its efforts in support of people living with the disease.
To join the Heritage Society, people who support the mission of the COPD Foundation need only to include the
Foundation in their wills or estate plans. In doing so, they help assure that the Foundation continues to have the
resources needed to maintain its commitment to improving the lives of the more than 24 million Americans living
with COPD.
Heritage Society members receive regular news about the COPD Foundation’s ongoing programs to increase the
diagnosis and treatment of COPD, to improve the lives of those living with COPD, to support research that leads to
improved therapies for COPD and to advocate for public policies that address the needs of those affected by COPD.
They will also receive unique invitations to attend select COPD Foundation events, and optional recognition on the
Heritage Society Honor Roll on the Foundation’s website.
Becoming a member is easy! Just notify the Foundation, in writing, that you have included the COPD Foundation in
your estate plans. For your convenience, you can notify the Foundation by filling out a COPD Foundation Heritage
Society Declaration of Intent form online at http://www.copdfoundation.org/TakeAction/Donate.aspx.
Founding
Benefactors
The COPD Foundation Founding Benefectors are individuals, founders and corporations and entities that have
contributed a total of $100,000 or more to the COPD Foundation as of June 30th, 2012.
Alpha-1 Foundation, Inc.
Anna-Maria and Stephen Kellen Foundation
AstraZeneca Pharmaceuticals LP
Boehringer Ingelheim Pharmaceuticals, Inc.
Centric Health Resources, Inc.
Collin and Patricia Scarborough
CSL Behring LLC
Estate of Albert N. Evans
12
Forest Laboratories, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Grayce B. Kerr Fund, Inc.
Grifols, Inc.
John A. McCrane
John and Diane Walsh
Lawrence and Rebecca Stern
COPD FOUNDATION 2012 Annual Report
Marie Fauth Charitable Fund
Mylan, Inc
Novartis Pharmaceuticals Corporation
Pfizer Pharmaceuticals
Sunovion Pharamaceuticals
Honor Gallery
During the 2012 Fiscal Year, the COPD Foundation received donations from individuals, foundations, and corporations
who share the Foundation’s commitment to programs that help improve the quality of life for all those affected by COPD.
The COPD Foundation thanks every donor for their contribution.
The COPD Foundation’s accomplishments would not have been reached without their commitment.
$1,000,000 +
Boehringer Ingelheim Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
$100,000 - 999,999
Anna-Maria and Stephen Kellen Foundation
CSL Behring LLC
Estate of Albert N. Evans
Forest Laboratories, Inc
GlaxoSmithKline
Grifols, Inc
Marie Fauth Charitable Fund
Pfizer Pharmaceuticals
$20,000 - 99,999
AstraZeneca Pharmaceuticals LP
John and Barbara Burns
Richard and Joan Cowlan
Mylan Inc.
National Jewish Health
Porter Novelli
Lawrence and Rebecca Stern
Sunovion Pharmaceuticals
University of Nebraska Medical Center
John and Diane Walsh
$5,000 - 19,999
1st Class Medical
AlphaNet, Inc.
Auto Club Speedway
Columbia Thoracic
Kathryn O. Costello
Dr. and Mrs. James and Katherine Crapo
Donald and Katherine Gray
Inova Labs, Inc.
Ted and Grace Anne Dorney Koppel
Saul and Eleanor Lerner Foundation
Vincent and Elisha Malanga
Medscape, LLC
Howard and Abby Milstein
Pilzer Family Foundation
Joseph F. Stein Family Foundation
Dr. Byron and Laurie Thomashow
Walter and Elaine Ulrich
Roy Vagelos
$1,000 - 4,999
American HomePatient
Dr. R. Graham Barr
Robert and Charlotte Barrett
Pamela R. Bird, Ph.D.
Margaret H. Brown
Gordon E. and May R. Cadwgan Foundation
JP Ciruso
Larry and Deirdre Cohen
CRH Foundation
Diamond Spring Dental Associates
John and Marilyn Dimling
Barnaby Donlon
Education for Health, The Athenaeum
Elenore and Maurice Rosenthal Foundation
Sam P. Giordano
Kenneth Irvine
Dr. Alfred Jaretzki, III
Tara Koppel
Thomas Larkins
Margo Lion
John and Carol Livingston
Dr. David M. Mannino, II
Susan McClanahan
MediCore Publishing, Inc.
Merrill Lynch
ndd Medical Technologies
New York Mets
Carlos and Robin Palomares
W. Hollis Peterson
Queens Ballpark Company L.L.C.
Dr. and Mrs. Stephen and Barbara Rennard
Sharron Resnick
Norma Revman
Roger and Brenda Gibson Family Foundation
Ron Rogers
Jack and Susan Rudin
Patricia M. Scarborough
Richard and Robin Schottenfeld
Charles and Susan Silberman
The Pulmonary Center
The Robert and Lynne Grossman Family Foundation
Marc and Caren Tischfield
Kathleen M. Toner
WebMD
Corey and Suzanne Weiss
Wayne (Chip) and Cindy Withers
Joe Zuraw
$500-999
A-Core Concrete Cutting
Aisha Ahmad
American Thoracic Society, Inc
John C. Barrett
Robert Berns
Michael and Mary Binchy
Mel Birge
Blondies III, LLC
Lillian K. Boettcher
Kevin Breslin
Jeff Bueker
Michael and Joanne Caputo
E. Virgil Conway
LeRoy and Corinne Davis
Danielle Dimston
Christopher Economos
Dr. Edward Eden
Electromed, Inc.
Stephen Frank
Dr. Stephen Freifeld
Stephen Glasser
Glen Gravender
Ellen Harkavy
Susan Harris
Peter Healy
Honeywell International Charity Matching
David and Michelle Horan
J.W. Didado Electric, Inc.
Dr. Donald Keck
Felix Khusid
Marion Kleinkramer
Ted and Carol Kramer
Beryl Loveless
The Miami Foundation
George Makris
Marketing Research Bureau, Inc.
Dr. William J. Martin
Mary Cushman North Living Trust
Carol Mauro
Michael Mayer
Col. and Mrs. R. W. Molyneux, Jr.
New York Downstate Association for
Respiratory Therapists
The Needham Family
Miriam A. O’Day
Oxygen To Go, LLC
Thomas Paolillo
Neal and Anita Pilzer
Jean-Marc Quach
Robert and Suzanne Reinbolt
Russell Matching Gifts Program
Schwab Charitable Fund
Gregg and Monique Seibert
Southwest Airlines
Dr. and Mrs. Harold and Diane Spalter
Dr. and Mrs. James and Terry Stoller
Renee B. Trachtenberg
Arthur Wilmes
Brian Woods
COPD FOUNDATION 2012 Annual Report
13
In Honor Of
William Ahner
Edna Albert
Nwandu Bell
Louis Boroson
Karyn Campbell
William Condon
Edwin Dahl
Maureen S. DeBolle
Diane Dona
Patricia Gribben
Norman E. Grill
Laura Grill
LaVerne M. Harris
Ernest Henry
Harold Herndon
Helene Herndon
Helene Horowitz
Deanna Jourdan
Daphne Kelley
Ann Klahr
Carole Kovnick
Malti Kulkarni
Beth Labasky
Christina LaBrecque
Chris Mode
Eddie Moore
Neal Altman-Abrams Artists
Rita R. Oeschger
Danica Patrick
Carol Pepper
Susan Schlosser
Frank Stumbo
JosephSurack
Joan Townshend
VCC Systems’ First Anniversary
John Waldron
Fred C. Walsh
Phyllis B. White
COPD F o u n d a t i o n
memorial gifts
Memorial gifts to the COPD Foundation are a thoughtful way to honor the memory of a loved one, friend, colleague or
neighbor who has died as a result of COPD while also supporting the Foundation’s caring mission.
The Foundation notifies the family of your contributions, but does not reveal the amount.
Memorials can be made online at: http://www.copdfoundation.org/TakeAction/Donate.aspx. When making a
memorial contribution, please provide the name of the deceased and the name and address of the family member to
be notified of the contribution.
To have memorial envelopes sent to a funeral home for the funeral of a loved one, please contact the Foundation
at [email protected], indicating the date and time of the funeral and the address to which the
envelopes should be sent.
14
COPD FOUNDATION 2012 Annual Report
In memory Of
Noreene Abarr
June Abatiello
Carleen Abel
Charles E. Adams
Loretta Adams
Gerald P. Ah Yo
Wade Ah You
Donna Aiola
Judith S. Alder
Sarita M. Allen
Beatrice Allen
Linda Alpers
Dennis Altendorfer
Antonio Alvarez Perez
Louise Anderson
Milton Anderson
Jackie J. Annis
Rex Armold
Rita Arndt
Aileen Askelson
Sherly J. Ayers
Sonny Ayres
Warren E. Babb
Thomas H. Babbitt
Rosa Mae L. Bailey Oddo
Jimmy L. Baker
Janie Baker
Janis Baker
Willie T. Ballard
Cice Balmar
Marie A. Balog
Saddie H. Balthrop
Thurba Barclay
Garry G. Barker
Rose Barnao
Edward Barnes
Art Barnett
Joan Barr
Lenore N. Basile
Doris Bauer
Richard Bayer
Brenda Beckham
Joe Begovich
Michael A. Bello
Rex Belton
Donna L. Benefiel
Betty Ann G. Bennett
Diane Benson
Arthur Berger
Barbara Berlin
Susan Bernstein
Luis Betancourt
Leo R. Bienvenu
Juanita Biser
Richard A. Bishop
Theresa P. Bittle
Genievive Blackwood
Jenivieve Blackwood
Edith K. Bolinger
Nora E. Borgemenke
Mary D. Borlick
Louis Boroson
Merle F. Bostian
Robert Boulter
Karen J. Brabon
Richard Brace
Michael J. Bradley
Dale Branchaud
Earnestine Braxton
Clarence Braysier
James Brennan
Lorraine Brice
Martha L. Bridge
Barbara J. Broetzmann
Ellen Bronok
Mary E. Bronski
Cordella Broussard
Margaret E. Brown
Raymond Brown
Andrea Bryant
Michael C. Buchanan
Sarah Burke
Mary J. Byrne
Jose C. Cabrera
F. Gerald Callan
Barbara Callen
Lucille Cameron
Ricky Cameron
Albert Campos
John Cannizzo
Louise B. Carr
Manly Carroll
Peter Carter
Carmello Casella
Earnest Cason
Josephine C. Catalano
Helen Cavalli
Joshua Cerda
Audra Chevalier
Anthony Cigna
Barbara Cirillo
James T. Clark
Tom Clarkin
Bess Clemens
Ben Clough
Renae Cohen
Doris M. Coll
Richard F. Colleoni
Velma Collier
Carter H. Collins
Dorothy Collins
Stanley M. Colvin
Jeanne Connick
Anne Cooley
Joseph Cortese
Timothy Costello
William Cozier
Doris Crane
Sherman “Buck” Crawford
Benjamin Crespi
John Crouch
Tom Cushman
Betty Cutlip
Edwin Dahl
Will Dale
Jacqueline B. D’Antuono
Carole A. Davidson
Aaron F. Davidson
Jeraldine B. Davis
LeRoy G. Davis
Amy W. Davis
Bettie W. Davis
Maureen S. DeBolle
Peggy R. Dees
Jeanne Deetz
Frances M. DeJohn
Michelina Del Monte
Richard A. DeLong
Tom Y. Denny
Barbara Derzack
Phyllis Desmarcus
Lawrence D’Esposito
Emile Desrochers
Shirley Dessner
Joshua M. Detweiler
Concetta Di Tinco
James Diamond
Sheila DiBello
Joseph Domerstad
Aunt Dorothy
Gertrude S. Douglas
Wayne Dowler
Michelle Downes
Patricia Downes-Bruzzese
Josephine Downing
Andy Doyle
Anne Dudley
Jonathan Dueker
Sharon S. Duke
Mike Dumas
June Duncan
Lawrence J. Dunn
Oscar Duvall
Marty Dwyer
Joann Eacott
Anna Earp
Marsha L. Eckel
Harold Edwards
Marie Elliot
Shirley Ellis
Donald Ensminger
Mary Lynn P. Epes
Lynn Epes
Flora A. Erickson
Francisco Escobar
Louisa Etchamendy
Louis Farris
Linda Fatz
John Feheis
Emily F. Ferguson
Barbara Ferrill
Kenneth Fessenden
Norma Jean Fetters
John Fetters
James Fields
Jim Fields
Randy Fields
Donald B. Finlayson
Mary Fisher
George Fix
Harold Fleisher
Betty Fletcher
Linda Fox
Janet S. Francis
Joseph W. Frank
Clarence E. Freburg
Lorraine Frederic
Roy H. Frye
Cyndi Fulenwider
Gloria J. Fundis
Rita Gabor
Mary A. Gainsforth
William T. Gallagher
Brent C. Galle
Angela M. Gallo
Alejandro Garcia
Phyllis M. Gardner
Kathleen S. Garland
James Garthright
Marilyn I. Gaynor
Gayle J. Gegenheimer
Mary Gehring
Sylvia Gelman
Carol T. Gibbs
Harlie Gibson
Yvette Giles
Michael Gilley
Carol Gionfriddo
Neva M. Gish
mom Gloria
Violet Golder
Al Goldstein
Esther Goldstein
Jose Gonzalez
Donna F. Goodknow Gowins
Elizabeth Goodrich
Juanita Goodwin
Betty Gorius
Lee A. Gray
Tom Green
Florence Greenstein
Anne Griemsmann
Norman E. Grill
Virginia Guinn
Anna Gulino
Deborah M. Haberlin
Nancy C. Hallada
Daniel Hallas
Betty Halward
Frank Hamilton
Shelley Hamrick
Kenneth H. Handy
William M. Hannen
Katherine Hannick
Peter Hansen
Wanda Hargus
Goldie D. Harper
James “Jimmy” Harris
David Harris
Eddie Harris
Sandi Haskell
Eileen Hassel
Chuck Haynes
Robert W. Heap
Earlyn Hebert
Art Heidelbach
Thomas Heintzelman
Curtis Heiserman
Alfred G. Heitmann
Michael C. Henkes
Mike Henkes
Ernest Henry
Ed Higgins
Dorothy M. Hill
Betty Hill
Sharon Hine
George Hirschmam
Marvin Hite
Bonnie G. Hochuli
Carol Holder
Inge Holst
Jack Holt
Carl Holtman
Shirley G. Hoover
Richard Horan
Mary A. Horiguchi
Ronald Hoskins
Harold Houk
Dorothy Howie
Pauline R. Hubbell
Tom Huddleston
Francis Hughes
Kathleen Hughes Barker
Paul Hurd
Pam Hutton
Francis “Bob” Iarossi
Linda (Shimel) Ide
Gloria Inlow
Susan Izard
Larry Jahnke
Jessie James
Robert W. Johnson
John D. Jones
Gloria Jones
Stanley Kamienski
Barbara Kane
Angela Kapeller
Lyle Karns
Frances D. Kauppinen
Barbara Kehlenbeck
COPD FOUNDATION 2012 Annual Report
15
Barbara A. Kelim
Barbara Kelium
Viola M. Kempf
Thomas D. Kennedy
Marian W Kergosien
Nylene Kerrigan
Bill Ketchen
Angie Kidwell
Gary Kieca
Claire Kiely
Lee Kincaid
Michael Klein
Nick Klein
Jeff Knight
Melba Knoblauch
Fotios Kopsachilis
Harriett Kosty
Victoria Kramer
Gloria Krassner
Barbara J. Kristof
Gloria Krosnoff
Malti Kulkarni
Bernard M. Kunz
Dorothy Kurka
Gilbert Kusibab
William C. Lahmer
Mauriec Lalonde
Orlando Lamas
Edward Lamiroult
Grandmother Lammy
Dolores Langston
Barbara Lanier
Helen M. Lansing
Jean R. Larkins
Mary L. Larson
Key Lavon
Linda Leady
Barbara Leal
Ronald D. Lederman
Margie M. Lee
Jane Leitner
Roy Lemons
Patty Lennington
Sandra Leon
Elizabeth Leonard
Mary B. Leone
Gean Lineberger
Al Lipinski
Rosine Liuzzo
Ralph Lloyd
Jane E. Loebbaka
Carl Lovelace
George A. Luby
Ben Ludwig
Francisco Luis
Fran Luscko
John E. Lynch
Doris Lyttle
Edward Maass
Elizabeth “Betty” MacDougall
Peggy Magurn
Adam Mahoney
James M. Major
JoAnne Mandley
Bob Mandt
Margaret Mantyla
Helen Marion
16
Claudia Marner
Jane Marston
Lorna P. Martin
Deanna Martin
Ernest C. Marvell
Mary J. Mason
Ronnie Mason
Vita F. Matton
Rosemary A. Maurer
Charlie L. Mayfield
David Mayhugh
Keith McBride
Joan E. McCarthy
John McCarthy
Mr McCarthy
Patrick McCarthy
Thomas McCauley
Tom McCauley
Joe McCloud
Jack McCollom
Mary H. McFerren
Michael P. McHugh
Roberta M. McKenry
John McKeown
Theodore McKinnie
Patricia D. McNeal
Linda McNutt
Winifred J. McQuiggan
Geraldine McQuillan
Edwin E. McVay
Barbara Meadows
Don Meeder
Jesse Meeks
Alice Mennitt
Frances Mercadante
Ellen Merrill
Nathan Messenger
Melvin “Chip” Mettler
Tomasz Mierkiewicz
Shirley M. Milburn
Mary E. Miller
Sally Miller
Barbara Mitchum
Elaine Molan
Kathleen A. Moloney
Marie A. Moloney
Patty’s Mom
Robert Montag
Robert J. Moore
Carey Moore
Eddie Moore
Sharron Morgan
Rose Morin
Audrey Morris
Arnelle Moss
J. Patrick Mulligan
Beverly A. Munday
Catherine Murray
Mary C. Mutilva
Phyllis Myers
Marjorie L. Narde
Marge Narde
Aleta M. Needham
Beverly Nekich
Linda M. New
Roland Newby
Billy B. Nichols
John J. Nolan
Mary T. Noone
Frank Norfleet
Mary North
Jeannie L. Northcutt
Naomi A. Novak
Albert O’Brien
George Ocskai
Donald F. Oehmke
Anne Ogulnik
Mario Olea
Michael Osmun
Camille Ouellette
Charlotte Ousley
Walter W. Pace
Roberta Painter
Syed A. Pasha
Mary Pataky
John F. Patrickson
Joseph H. Pavlich
Marie Peck
Connie Pepple
Renee Perry
Dr. Tom Petty
Lana Perusse
Phyllis Phillips
Marie Eunice Phillips Voss Mucha
Maryellen Pierson
Chick Plummer
Richard G. Poehner
Peter Poltersdorf
Richard L. Pousen
William Powell
Ersie Puckett
Odis Pyron
Vernon “Chip” R. Ackerson
Bruce Rafter
James L. Rakes
Robert Reicherter
Carol L. Reid
Robert Reigherter
Manfred Reiss
Kim Reno
Gertrude Ribet
Joseph C. Richard
Cheryl L. Richardson
Carylan Richerson
Iris S. Richmond-Kirby
Betty Ritchey
Mary Ann Rivard
Peter Rizzo
Charlene “Punkin” Roach
Art Roberts
Bonalyn C. Robinson
Beth Robinson
Elsbeth Robinson
Frances M. Roeckers
Jerry W. Rogers
Irmgard Romeika
Gerry Rose
Ann Rosenberg
William S. Royston
Sydney Rubenfeld
David D. Rudd
John “Jack” Ruscoe
Charles V.B. Rush
Nicholas Russell
COPD FOUNDATION 2012 Annual Report
Beverly Russo
Arlene Sabin
Becky Sadoski
Robert Sadowski
Steven Safko
Leland Saga
Kathleen Santamaria
Esther Sapien
George Sarkesian
Rosemarie I. Sauer
Charles Saunders
Rosemarie I. Saver
Salvatore Scalice
George Scamby
Vicki Scardina
Gehl Schaefer
Eleanor Schioppa
Wendy S. Schoenike
John Scholer
Gertrude Schotter
Trudy Schotter
Georgia Schramm
Judith Schroeder
Marvelle Schuster
Joseph S. Scott
Janice Senn
Howard Seplowe
Richard Severance
Roberta Shapiro
Irma Sheridan
David G. Shields
Dave Shields
Betty L. Shives
Allen Shorr
Sharon L. Shreve
Richard D. Silva
G. Mathis Sleeper
Harland Smilack
Barbara M. Smith
Ruth S. Smith
Ernest Smith
Jack Smith
Ronald Smith
Milton J. Sontheimer
Ivan Sorensen
Adele J. Sorese
Czeslaw “Chester” Sowa
Robert Spellman
Bill Sporman
John Staffiari
Sandra Stanich
Elmer G. Stanley
Myrna L. Statman
Rae Steiger
Bruce Stevenson
James E. Stinchcomb
Reva Strauss
Julius Sughrue
Anna W. Sullivan
Daniel Sullivan
John Sullivan
Lillian Sullivan
Norma Jean Summer
Steven Sutton
Lewis Swartz
Bette Jo Switzer Robertson
Nina Syden
Joseph Szabo
Jack Taber
Jane Taliento
Jacquelyn Tarrer
Ragini Tatake
Jean Tavano
Margaret Taylor
Rhonda W. Terrell
Thomas C. Theodos
Leon Thielman
Robert F. Thoens
John D. Thompson
Evelene Thompson
Jennifer L. Tietgen
Laura Tolbert
Alfonso Tonelli
Marjorie Toomey
Robert Toranto
Jolene Townsend
Harold Trepp
Jimmie Tullos
Carole J. Tunnell
Vicki Turner
Betty Underberg
Charmion R. Valenta
Ray Van Benthuysen
Phyllis VanNest
David Vaughn
Robert E. Vawter
Kathryn Voigt
Eleanor R. Walker
Jimmie D. Wall
Doug Wallis
Helen Chase Walsh
Millie P. Waltman
Thelma Wanders
Benny Wardlow
Leroy E. Warren
Jacob J. Weaver
Betty J. Wechling
Sandra Weickum
Karen Weiland
Joyce Wendt
Helen Wenzer
Robert Wesley
Carl West
Kathleen Westberg
Eddie Westfield
James W. Wexler
Crist Wheeler
Theresa Wheeler
Patrick M. Whiteley
Beverly Whiteside
Gil Williams
Charlotte Wilson
Corinne Wilson
Margie Wilson
Ted Wilson
Garrett “Steve” Wimmer
William H. Windhorst
Delbert L. Wolfe
Esther L. Wright
Mary Wright
Masayuki Zoriki
Rosemary Zweigbaum
Supporters
Contributed Grants and Other Funds (or products)
Nancy Cartwright
Allen Covert
Lyn-Z Adams Hawkins
Inova Labs, Inc.
Bruce Jenner
R2Integrated
Rob Riggle
Geoff Stults
Kristy Swanson
Organizations who partnered on projects
Alpha-1 Foundation
American Association for Respiratory Care
American Medical Sales and Service
Healthy Interactions
NASCAR
MedscapeCME
University of Nebraska Medical Center
National Jewish Health
Healthy Trucking Association of America
DRIVE4COPD Sponsors & Major Contributors
Boehringer Ingelheim Pharmaceuticals, Inc.
Corporate Grants
AstraZeneca Pharmaceuticals LP
Auto Club Speedway
Boehringer Ingelheim Pharmaceuticals, Inc.
CSL Behring LLC
Forest Laboratories, Inc.
GlaxoSmithKline
Grifols, Inc.
Medscape LLC
Mylan Inc.
National Jewish Health
Novartis Pharmaceuticals Corporation
Pfizer Pharmaceuticals
Porter Novelli
University of Nebraska Medical Center
WebMD
Special Events Partners
Elenore and Maurice Rosenthal Foundation
Forest Laboratories, Inc.
Gordon E. and May R. Cadwgan Foundation
Grifols, Inc.
Harper Collins Publishers
Inova Labs, Inc.
JMI
Kleiger Foundation
LC Marketing
Marketing Research Bureau, Inc.
MediCore Publishing, Inc.
Merrill Lynch
Mylan Inc.
New York Downstate Association for Respiratory
Therapists
New York Mets
New York Theatre Ballet
Novartis Pharmaceuticals Corporation
Oxygen To Go, LLC
Pilzer Family Foundation
The Pulmonary Center
Queens Ballpark Company L.L.C.
Rimrob Corporation
Southwest Airlines
Sunovion Pharmaceuticals Inc.
Advertising Partners
Acorn Stairlifts, Inc.
American Association For Homecare
American HomePatient
American Legacy Foundation
Baxter Healthcare Corporation
Biosector2
Chart SeQual Technologies, Inc.
CRH Foundation
CSL Behring LLC
Electromed, Inc.
Fisher & Paykel Healthcare Ltd
Grifols, Inc.
Hill-Rom, Inc.
ICC Lowe, LLC
Ingen Technologies, Inc.
Inova Labs, Inc.
Invacare Corporation
MedicAlert Foundation
ndd Medical Technologies
NeilMed Pharmaceuticals, Inc.
Nephron Pharmaceuticals Corporation
New Industries Corporation
Nonin Medical, Inc.
Novartis Clinical Operations, Inc.
Oncimmune USA, LLC
Oximeter Plus Inc.
Oxy-View, Inc.
Pari Respiratory Equipment, Inc.
PHD USA
Philips Home Healthcare Solutions
Philips Respironics Inc.
Pivot Design, Inc.
Polar Wrap, LLC
Resolutions LLC
Rx Stat, Inc.
Vapotherm, Inc.
Bronchiectasis Registry:
Anna-Maria and Stephen Kellen Foundation
COPD Research Registry
Grifols, Inc.
Mylan, Inc.
COPD FOUNDATION 2012 Annual Report
17
www.copdfoundation.org | www.DRIVE4COPD.org | 2937 SW 27th Avenue, Suite 302, Miami, FL 33133 | 20 F Street NW, Suite 200-A, Washington, DC 20001